lenalidomide has been researched along with Anemia, Macrocytic in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (85.71) | 24.3611 |
| 2020's | 5 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, A; Miura, I; Sakai, H | 1 |
| Karsan, A; Martinez-Høyer, S | 1 |
| Ichikawa, M | 1 |
| Avilés, A; Candelaria, M; Fabian-Morales, E; Gutierrez, O; Palacios-Campos, A | 1 |
| Döhner, K; Gabdoulline, R; Ganser, A; Ganster, C; Germing, U; Göhring, G; Gutermuth, A; Haase, D; Haferlach, C; Haferlach, T; Heuser, M; Kandziora, C; Klement, P; Klesse, S; Kobbe, G; Koenecke, C; Kröger, N; Krönke, J; Kubasch, AS; Meggendorfer, M; Mies, A; Panagiota, V; Platzbecker, U; Schiller, J; Schlegelberger, B; Schroeder, T; Shahswar, R; Shirneshan, K; Sperr, WR; Thiede, C; Thol, F; Valent, P | 1 |
| Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E | 1 |
| Chaudhry, QUN; Iftikhar, R; Khan, MA; Mahmood, SK; Satti, TM; Shahbaz, N | 1 |
| Chisti, MM; Fennell, T; Sanders, DS | 1 |
| Scott, LJ; Syed, YY | 1 |
| Gironella, M; López-Andreoni, L; Mallo, M; Martínez-Morgado, N; Ortega, M; Sánchez-Morata, C; Solé, F; Valcárcel, D; Vallespí, T | 1 |
| Arceci, RJ; Atsidaftos, E; Blanc, L; Bodine, DM; Ebert, BL; Ellis, SR; Farrar, JE; Gazda, HT; Landowski, M; Lipton, JM; Liu, JM; Markello, TC; Muir, E; Narla, A; Singh, SA; Vlachos, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Sakurai, T; Yamada, M; Yoshida, M | 1 |
| Bokorova, R; Brezinova, J; Cermak, J; Cervinek, L; Fuchs, O; Hajkova, H; Jonasova, A; Kostecka, A; Michalova, K; Mikulenkova, D; Neuwirtova, R; Polak, J; Siskova, M; Sponerova, D; Vostry, M | 1 |
| Belickova, M; Cermak, J; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Merkerova, MD; Michalova, K; Stara, E; Zemanova, Z | 1 |
| Barančik, M; Breier, A; Gibalová, L; Jonášová, A; Messingerová, L; Poleková, L; Šereš, M; Sulová, Z | 1 |
| Bazargan, A; Giv, MJ; Yoosuff, A | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G | 1 |
| Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R | 1 |
| Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A | 1 |
| Buckstein, R; Rezmovitz, J; Wells, RA | 1 |
| Balaian, E; Bornhäuser, M; Ehninger, G; Germing, U; Haase, D; Mohr, B; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Schönefeldt, C; Schuster, C; Tuve, S; von Bonin, M; Wermke, M | 1 |
| Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Chmarzyńska, E; Dwilewicz-Trojaczek, J; Jędrzejczak, WW; Koperski, Ł; Pastwińska, A; Paszkowska-Kowalewska, M; Ziarkiewicz, M; Ziarkiewicz-Wróblewska, B | 1 |
| Komrokji, R; List, AF; Padron, E | 2 |
| Alimena, G; Breccia, M; Cannella, L; Latagliata, R; Loglisci, G; Oliva, EN; Salaroli, A; Santopietro, M | 1 |
| Sanchez, JF | 1 |
| Aguilar, JL; Baumann, T; Calvo, X; Cervantes, F; Colomer, D; Costa, D; Díaz-Beyá, M; Esteve, J; Maffioli, M; Martínez-Trillos, A; Nomdedeu, B; Nomdedeu, M; Rozman, M | 1 |
| Katayama, Y | 1 |
| Komrokji, RS; List, AF | 1 |
| Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; Finelli, C; Galimberti, S; Ghio, R; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Rigolino, C; Rodà, F; Sanpaolo, G; Volpe, A | 1 |
| Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R | 1 |
8 review(s) available for lenalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Mechanisms of lenalidomide sensitivity and resistance.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Angiogenesis Inhibitors; Antineoplastic Agents; Autophagy; Cell Differentiation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokines; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Megakaryocytes; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Ubiquitin-Protein Ligases | 2020 |
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Topics: Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Biology and treatment of the 5q- syndrome.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Deletion; Humans; Lenalidomide; Thalidomide | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Genes, p53; Haploidy; Humans; Lenalidomide; MicroRNAs; Molecular Targeted Therapy; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2011 |
5 trial(s) available for lenalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Myelodysplastic Syndromes; Reproducibility of Results; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2015 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome | 2016 |
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Topics: Aged; Aged, 80 and over; Anemia, Macrocytic; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2016 |
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Topics: Aged; Anemia, Macrocytic; Apoptosis; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Forkhead Transcription Factors; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation; Genetic Association Studies; Humans; Immunity, Innate; Lenalidomide; Male; MicroRNAs; Models, Genetic; Myelodysplastic Syndromes; Ribosomal Proteins; Signal Transduction; Thalidomide | 2013 |
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Health Status; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Quality of Life; Risk; Severity of Illness Index; Thalidomide; Treatment Outcome | 2013 |
22 other study(ies) available for lenalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2022 |
[Management of lower-risk myelodysplastic syndromes].
Topics: Anemia, Macrocytic; Darbepoetin alfa; Humans; Japan; Lenalidomide; Myelodysplastic Syndromes; Risk Assessment | 2020 |
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
Topics: Aged; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2020 |
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Protein Phosphatase 2C; Retrospective Studies | 2021 |
[Lenalidomide desensitization in a patient with 5q- syndrome].
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunologic Factors; Lenalidomide | 2017 |
Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
Topics: Anemia, Macrocytic; Calreticulin; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Stevens-Johnson Syndrome | 2018 |
MDS with 5q deletion and rare
Topics: Anemia, Macrocytic; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Mastocytosis; Middle Aged; Mutation; Myelodysplastic Syndromes | 2019 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Topics: Adolescent; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Phenotype; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribosomal Proteins; Thalidomide | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Fatal Outcome; Humans; Lenalidomide; Male; Stevens-Johnson Syndrome; Thalidomide | 2013 |
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Single Nucleotide; RNA Splicing; RNA, Messenger; Signal Transduction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2015 |
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Topics: Aged; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome-Wide Association Study; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Primary Cell Culture; RNA Splicing; Signal Transduction; Thalidomide | 2015 |
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Lung; Sarcoidosis, Pulmonary; Thalidomide; Tomography, X-Ray Computed | 2015 |
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Health Care Costs; Humans; Lenalidomide; Models, Economic; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Technology Assessment, Biomedical; Thalidomide | 2016 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2016 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Thalidomide; Thrombocytosis | 2010 |
Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythroid Cells; Exanthema; Humans; Lenalidomide; Ribosomal Proteins; Thalidomide | 2011 |
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Topics: Amino Acid Substitution; Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Middle Aged; Mutation, Missense; Myelodysplastic Syndromes; Phenylalanine; Thalidomide; Treatment Outcome; Valine | 2011 |
The 5q- syndrome: biology and treatment.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis | 2012 |